Teva Pharmaceutical Industries Limited (TEVA) PEG Ratio
N/A
PE ratio relative to earnings growth — is the valuation justified?
—
PEG Ratio
—
Current Price
$36.46
TTM EPS
$0.60
P/E Ratio
60.77
Growth Rate
—
N/A
Sector
Healthcare
Drug Manufacturers - Specialty & Generic
Calculated
8/18/2026
9:46:26 AM
PEG Ratio Unavailable
EPS growth rate unavailable
Peer Comparison
Sample Size
3 peers
Industry Median PEG
2.73
25th Percentile
1.49
75th Percentile
8.88
Symbol
Company
PEG
P/E
Growth
vs TEVA
NVS
Novartis AG
1.49
22.9
15.4%
—
BMY
Bristol-Myers Squibb Company
2.73
14.2
5.2%
—
AMGN
Amgen Inc.
8.88
26.1
2.9%
—
How to Interpret PEG Ratio
PEG < 1.0 — Potentially Undervalued. The stock may be priced below its earnings growth rate, suggesting a potential buying opportunity.
PEG 1.0–2.0 — Fairly Valued. The stock price is roughly in line with its earnings growth. A PEG of 1.0 is often considered "fair value."
PEG > 2.0 — Potentially Overvalued. The stock may be priced above what its earnings growth justifies.
Limitations:PEG ratios are less reliable for financial firms (earnings driven by interest margins), companies with negative/zero earnings growth, and hypergrowth companies (>100% growth) where the ratio may appear misleadingly low. Always use PEG alongside other valuation metrics.
